Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aerovate Therapeutics, Inc.

9.80
0.0000
Volume:- -
Turnover:2.77M
Market Cap:284.05M
PE:-5.76
High:9.80
Open:9.80
Low:9.80
Close:9.80
52wk High:884.98
52wk Low:9.80
Shares:28.99M
Float Shares:11.96M
Volume Ratio:- -
T/O Rate:- -
Dividend:2.40
Dividend Rate:24.49%
EPS(TTM):-1.7025
EPS(LYR):-2.4361
ROE:-59.01%
ROA:-36.18%
PB:3.79
PE(LYR):-4.02

Loading ...

Company Profile

Company Name:
Aerovate Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.